Summary
Objective: The prognostic role of lactate dehydrogenase (LDH) in urinary system cancer is still controversial. Thus, we conducted a meta-analysis to assess the prognostic significance of LDH for patients with urinary system cancer. Methods: We searched the PubMed, Embase, Springer and CNKI databases for studies published from January 1991 to February 2015 associated with LDH and urinary system cancer. Study quality was assessed using the Newcastle-Ottawa Scale. After careful review, survival data were extracted from eligible studies. We used pooled hazard ratios (HRs) to estimate the effect of LDH on overall survival (OS) and progression-free survival (PFS). Results: 44 studies meeting the criterion were included. High expression of LDH was significantly correlated with poor OS in urologic cancer (pooled HR 1.93, 95% confidence interval (CI) 1.81-2.07; p < 0.001). The pooled HRs showed significant difference in PFS between LDH over expression group with LDH low expression group (Pooled HR 1.95, 95% CI 1.61-2.36; p < 0.001) in urologic cancer. Conclusion: High serum LDH is associated with OS and PFS in patients with urinary system cancer, and it is an effective biomarker of prognosis in patients with urologic cancer.
Journal Section:
Original Article
References
1.
Liao AC, Li CF, Shen KH, et al.: Loss of lactate dehydrogenase B subunit expression is correlated with tumour progression and independently predicts inferior disease-specific survival in urinary bladder urothelial carcinoma. Pathology 2011;43:707-712.
[PubMed]
2.
Tas F, Aykan F, Alici S, et al.: Prognostic factors in pancreatic carcinoma: Serum LDH levels predict survival in metastatic disease. Am J Clin Oncol 2001;24:547-550.
[PubMed]
3.
Zhou T, Hong S, Hu Z, et al.: A systemic inflammation-based prognostic scores (mGPS) predicts overall survival of patients with small-cell lung cancer. Tumour Biol 2015;36:337-343.
[PubMed]
4.
Wu JX, Chen HQ, Shao LD: Long-term follow-up and prognostic factors for advanced thymic carcinoma. Medicine (Baltimore) 2014;93:e324.
[PubMed]
5.
Chen J, Sun MX, Hua YQ, Cai ZD: Prognostic significance of serum lactate dehydrogenase level in osteosarcoma: A meta-analysis. J Cancer Res Clin Oncol 2014;140:1205-1210.
[PubMed]
6.
Aben KK, Heskamp S, Janssen-Heijnen ML, et al.: Better survival in patients with metastasised kidney cancer after nephrectomy: A population-based study in the Netherlands. Eur J Cancer 2011;47:2023-2032.
[PubMed]
7.
Aparicio AM, Harzstark AL, Corn PG, et al.: Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 2013;19:3621-3630.
[PubMed]
8.
Hannisdal E, Fossa SD, Høst H: Blood tests and prognosis in bladder carcinomas treated with definitive radiotherapy. Radiother Oncol 1993;27:117-122.
[PubMed]
9.
Yang MH, Chen KK, Yen CC, et al.: Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan. Urology 2002;59:681-687.
[PubMed]
10.
Nakano K, Komatsu K, Kubo T, et al.: Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib. Jpn J Clin Oncol 2013;43:1023-1029.
[PubMed]
11.
Kume H, Suzuki M, Fujimura T, et al.: Docetaxel as a vital option for corticosteroid-refractory prostate cancer. Int Urol Nephrol 2011;43:1081-1087.
[PubMed]
12.
Berruti A, Mosca A, Tucci M, et al.: Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 2005;12:109-117.
[PubMed]
13.
Humphrey PA, Halabi S, Picus J, et al.: Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone-refractory prostate cancer: Results from cancer and leukemia group B 150005/9480. Clin Genitourin Cancer 2006;4:269-274.
[PubMed]
14.
Furuya Y, Akimoto S, Akakura K, et al.: Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer. Urol Int 1998;60:28-32.
[PubMed]
15.
Nakagawa T, Hara T, Kawahara T, et al.: Prognostic risk stratification of patients with urothelial carcinoma of the bladder with recurrence after radical cystectomy. J Urol 2013;189:1275-1281.
[PubMed]
16.
The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. http://www.Ohri.Ca/programs/clinical_epidemiology/oxford.Asp.
17.
Cetin B, Afsar B, Deger SM, et al.: Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma. Int Urol Nephrol 2014;46:1081-1087.
[PubMed]
18.
Culp SH, Tannir NM, Abel EJ, et al.: Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 2010;116:3378-3388.
[PubMed]
19.
Poprach A, Pavlik T, Melichar B, et al.: Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines. Urol Oncol 2014;32:488-495.
[PubMed]
20.
Atkinson BJ, Kalra S, Wang X, et al.: Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol 2014;191:611-618.
[PubMed]
21.
Amato RJ, Flaherty A, Zhang Y, et al.: Clinical prognostic factors associated with outcome in patients with renal cell cancer with prior tyrosine kinase inhibitors or immunotherapy treated with everolimus. Urol Oncol 2014;32:345-354.
[PubMed]
22.
Abel EJ, Culp SH, Tannir NM, et al.: Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol 2011;60:1273-1279.
[PubMed]
23.
Jeppesen AN, Jensen HK, Donskov F, et al.: Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma. Br J Cancer 2010;102:867-872.
[PubMed]
24.
Donskov F, von der Maase H: Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006;24:1997-2005.
[PubMed]
25.
Kamba T, Yamasaki T, Teramukai S, et al.: Improvement of prognosis in patients with metastatic renal cell carcinoma and Memorial Sloan-Kettering Cancer Center intermediate risk features by modern strategy including molecular-targeted therapy in clinical practice. Int J Clin Oncol 2014;19:505-515.
[PubMed]
26.
Shinohara N, Abe T, Mochizuki T, et al.: Is Memorial Sloan-Kettering Cancer Center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era? Urol Oncol 2013;31:1276-1282.
[PubMed]
27.
Armstrong AJ, George DJ, Halabi S: Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol 2012;30:3402-3407.
[PubMed]
28.
Richey SL, Culp SH, Jonasch E, et al.: Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol 2011;22:1048-1053.
[PubMed]
29.
Peccatori J, Barkholt L, Demirer T, et al.: Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer 2005;104:2099-2103.
[PubMed]
30.
Inoue R, Takahashi A, Takasugi S, et al.: [Prognostic factors in patients with metastatic renal cell carcinoma]. Hinyokika Kiyo 2010;56:75-79.
[PubMed]
31.
Escudier B, Choueiri TK, Oudard S, et al.: Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: New paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol 2007;178:1901-1905.
[PubMed]
32.
Suppiah R, Shaheen PE, Elson P, et al.: Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 2006;107:1793-1800.
[PubMed]
33.
Vermaat JS, van der Tweel I, Mehra N, et al.: Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. Ann Oncol 2010;21:1472-1481.
[PubMed]
34.
Patil S, Figlin RA, Hutson TE, et al.: Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2011;22:295-300.
[PubMed]
35.
Coumans FA, Doggen CJ, Attard G, et al.: All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer. Ann Oncol 2010;21:1851-1857.
[PubMed]
36.
Goodman OB Jr, Fink LM, Symanowski JT, et al.: Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors. Cancer Epidemiol Biomarkers Prev 2009;18:1904-1913.
[PubMed]
37.
Naruse K, Yamada Y, Aoki S, et al.: Lactate dehydrogenase is a prognostic indicator for prostate cancer patients with bone metastasis. Hinyokika Kiyo 2007;53:287-292.
[PubMed]
38.
Yamada Y, Nakamura K, Aoki S, et al.: Lactate dehydrogenase, Gleason score and HER-2 overexpression are significant prognostic factors for M1b prostate cancer. Oncol Rep 2011;25:937-944.
[PubMed]
39.
Schellhammer PF, Chodak G, Whitmore JB, et al.: Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial. Urology 2013;81:1297-1302.
[PubMed]
40.
Sasaki T, Onishi T, Hoshina A: Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis. Prostate Cancer Prostatic Dis 2011;14:248-252.
[PubMed]
41.
Furuya Y, Nagakawa O, Fuse H: Prognostic significance of changes in short-term prostate volume and serum prostate-specific antigen after androgen withdrawal in men with metastatic prostate cancer. Urol Int 2003;70:195-199.
[PubMed]
42.
Taplin ME, George DJ, Halabi S, et al.: Prognostic significance of plasma chromogranin A levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology 2005;66:386-391.
[PubMed]
43.
Saito T, Hara N, Kitamura Y, Komatsubara S: Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer. Urology 2007;70:702-705.
[PubMed]
44.
Ferraldeschi R, Nava Rodrigues D, Riisnaes R, et al.: PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol 2015;67:795-802.
[PubMed]
45.
Templeton AJ, Pezaro C, Omlin A, et al.: Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer 2014;120:3346-3352.
[PubMed]
46.
D'Amico AV, Chen MH, Cox MC, et al.: Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer. Urology 2005;66:571-576.
[PubMed]
47.
Halabi S, Lin CY, Kelly WK, et al.: Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2014;32:671-677.
[PubMed]
48.
Narita S, Tsuchiya N, Yuasa T, et al.: Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer. Int J Clin Oncol 2012;17:204-211.
[PubMed]
49.
Omlin A, Pezaro C, Mukherji D, et al.: Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol 2013;64:300-306.
[PubMed]
50.
Tucci M, Mosca A, Lamanna G, et al.: Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease. Prostate Cancer Prostatic Dis 2009;12:94-99.
[PubMed]
51.
Feron O: Pyruvate into lactate and back: From the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol 2009;92:329-333.
[PubMed]
52.
Gatenby RA, Gillies RJ: A microenvironmental model of carcinogenesis. Nat Rev Cancer 2008;8:56-61.
[PubMed]
53.
Warburg O: On the origin of cancer cells. Science 1956;123:309-314.
[PubMed]
54.
Augoff K, Hryniewicz-Jankowska A, Tabola R: Lactate dehydrogenase 5: An old friend and a new hope in the war on cancer. Cancer Lett 2015;358:1-7.
[PubMed]
© 2016 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2016
You do not currently have access to this content.
